Tübingen, Germany

Benjamin Petsch

USPTO Granted Patents = 42 

 

 

Average Co-Inventor Count = 3.2

ph-index = 13

Forward Citations = 481(Granted Patents)


Location History:

  • Tubingen, DE (2014)
  • Tuebingen, DE (2017)
  • Tübingen, DE (2017 - 2024)

Company Filing History:


Years Active: 2014-2025

Loading Chart...
Loading Chart...
Loading Chart...
42 patents (USPTO):Explore Patents

Title: Innovations and Contributions of Benjamin Petsch in Vaccine Development

Introduction: Benjamin Petsch, an accomplished inventor based in Tübingen, Germany, has made significant strides in the field of vaccine development, boasting an impressive portfolio of 35 patents. His work focuses primarily on innovative treatments and prophylactic measures against highly infectious viruses, particularly in response to the global health challenges posed by Henipaviruses and coronaviruses.

Latest Patents: Among his notable recent patents is the Henipavirus vaccine, which encompasses artificial nucleic acids and polypeptides aimed at treating or preventing infections caused by Hendra virus and Nipah virus. This invention not only outlines the potential vaccine but also proposes methods for administering the artificial nucleic acid and associated compositions. Another prominent patent is the Coronavirus vaccine, which details a nucleic acid suitable for halting infections caused by SARS-COV-2, the virus responsible for COVID-19. This patent includes the use of lipid nanoparticles in the formulation of vaccines and compositions, further expanding the toolkit available for combating infectious diseases.

Career Highlights: Benjamin Petsch has been instrumental in advancing vaccine technology through his contributions at various esteemed companies, including CureVac SE and CureVac AG. His work is recognized for breaking new ground in the creation of mRNA-based vaccines, which have become a pivotal response mechanism to viral outbreaks.

Collaborations: During his career, Benjamin has collaborated with notable professionals in the field, such as Thomas Kramps and Margit Schnee. These partnerships have facilitated innovation and expedited the development of groundbreaking vaccine solutions that address urgent health threats.

Conclusion: Benjamin Petsch exemplifies the spirit of innovation in medical research, particularly in vaccine development against deadly viruses. With a robust patent portfolio and a commitment to collaborative efforts, he continues to pave the way for advancements that hold the promise of safeguarding global health against infectious diseases. His contributions are a testament to the importance of innovative thinking in the face of contemporary health challenges.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…